LONDON and PHILADELPHIA – October [14], 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a life sciences company developing innovative, targeted oncology drugs, today announces the Company will present the most recent data analysis from the ongoing Phase 1a trial of Faridoxorubicin (AVA6000) and the design of the FOCUS-01 trial of FAP-Exd (AVA6103) in two poster presentations at the European Society for Medical Oncology (ESMO) 2026 Congress, to be held in Madrid from October 23-27, 2026.
A presentation on October 26, 2026 will include the progression-free survival (PFS) data in patients with salivary gland cancer (SGC) as well as FAPI-PET imaging data from this expansion cohort from the ongoing Phase 1a/1b trial of Faridoxorubicin (AVA6000) in patients with Fibroblast Activation Protein (FAP)-positive solid tumors
A second presentation featuring the design of the Phase 1 FOCUS-01 trial will include updated preclinical data on AVA6103.
Details of the presentations
A Phase 1a/1b trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with salivary gland cancers
Authors: Renata Ferrarotto, Robert Metcalf, Steph A. Pang, William D. Tap, et. al, Alan L. Ho
Poster number: 1549P
Time: Monday October 26, 12:00-12:45pm CET
A phase I trial of FAP-Exd (AVA6103), a Fibroblast Activation Protein (FAP)-enabled pre|CISION® peptide-drug conjugate delivering sustained tumor microenvironment (TME) release of exatecan in patients with FAP-positive solid tumors
Authors: Alexander I. Spira, Nehal J. Lakhani, Judy S. Wang, Muhammad R. Khawaja, Ruairidh Edwards, Karen Campbell, Curtis Rink, Christiana Nikolova, David Liebowitz
Poster number: 1134eTiP
Time: e-Poster TIP Session